The HIV Prevention Trials Network (HPTN) has launched a new study, HPTN 083, to evaluate whether injectable cabotegravir (CAB) can safely protect cisgender men who have sex with men (MSM)… Read More
Publication of HPTN 052 Final Results: HIV Treatment Offers Durable Prevention of HIV Transmission in Serodiscordant Couples
The HIV Prevention Trials Network (HPTN) announced that the final results of the HPTN 052 study were published in the New England Journal of Medicine (NEJM). This pivotal study demonstrated that antiretroviral… Read More
